4 Reasons Amarin Stock Could Tumble Even Further

Cory Renauer, The Motley Fool
·4-min read
4 Reasons Amarin Stock Could Tumble Even Further

Amarin (NASDAQ: AMRN) investors who had been expecting a sales explosion have instead seen the bottom fall out from under their shares, and the company's second-quarter earnings report was less than encouraging. The only product Amarin has on the market, Vascepa, is a fish oil supplement that's approved for use in combination with statins to reduce the risk of heart attacks. An unfavorable ruling in favor of generic drugmakers seeking to market their own FDA-approved formulations of Vascepa already appears to be having a negative effect on its sales growth.